NYSEAMERICAN:PTNPalatin Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.58 +0.02 (+3.04 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.55Now: $0.58▼$0.6050-Day Range N/A52-Week Range$0.36Now: $0.58▼$1.13Volume67,512 shsAverage Volume1.98 million shsMarket Capitalization$132.28 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Palatin Technologies has a potential upside of 614.5% from its current price of $0.56.Amount of Analyst CoveragePalatin Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesPalatin Technologies has received 424 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPalatin Technologies has received 297 “underperform” votes. (Add your “underperform” vote.)Community SentimentPalatin Technologies has received 58.81% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote “Outperform” if you believe PTN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone+1-609-4952200Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees19 Outstanding Shares229,258,000Market Cap$132.28 million Next Earnings Date9/10/2020 (Estimated) OptionableNot Optionable $0.58 +0.02 (+3.04 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PTN News and Ratings via Email Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Palatin Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Palatin Technologies. When is Palatin Technologies' next earnings date? Palatin Technologies is scheduled to release its next quarterly earnings announcement on Thursday, September 10th 2020. View our earnings forecast for Palatin Technologies. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). During the same period in the prior year, the firm posted ($0.03) EPS. View Palatin Technologies' earnings history. What price target have analysts set for PTN? 2 brokers have issued 1 year price objectives for Palatin Technologies' stock. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 593.2% from the stock's current price. View analysts' price targets for Palatin Technologies. Has Palatin Technologies been receiving favorable news coverage? Headlines about PTN stock have been trending very positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Palatin Technologies earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Palatin Technologies. Are investors shorting Palatin Technologies? Palatin Technologies saw a decrease in short interest in July. As of July 31st, there was short interest totaling 11,070,000 shares, a decrease of 11.3% from the July 15th total of 12,480,000 shares. Based on an average daily volume of 2,670,000 shares, the short-interest ratio is presently 4.1 days. Currently, 5.2% of the company's shares are sold short. View Palatin Technologies' Short Interest. Who are some of Palatin Technologies' key competitors? Some companies that are related to Palatin Technologies include Renalytix Ai (RENX), Arch Capital Group (AWH), Profound Medical (PRN), Volpara Health Tech (VHT), MaxCyte (MXCT), Exagen (XGN), Akumin (AKU), Senseonics (SENS), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), SQI Diagnostics (SQD), Genedrive (GDR) and BARD1 Life Sciences (BD1). View all competitors. What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), AcelRx Pharmaceuticals (ACRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). Who are Palatin Technologies' key executives? Palatin Technologies' management team includes the following people: Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)Burns McClellan, VP of Investor Relations What is Palatin Technologies' stock symbol? Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN." Who are Palatin Technologies' major shareholders? Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include WINTON GROUP Ltd (0.83%), First Trust Advisors LP (0.19%) and Russell Investments Group Ltd. (0.03%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View institutional ownership trends for Palatin Technologies. Which major investors are buying Palatin Technologies stock? PTN stock was acquired by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Russell Investments Group Ltd., and First Trust Advisors LP. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr, and Stephen T Wills. View insider buying and selling activity for Palatin Technologies. How do I buy shares of Palatin Technologies? Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Palatin Technologies' stock price today? One share of PTN stock can currently be purchased for approximately $0.58. How big of a company is Palatin Technologies? Palatin Technologies has a market capitalization of $132.28 million. Palatin Technologies employs 19 workers across the globe. What is Palatin Technologies' official website? The official website for Palatin Technologies is www.palatin.com. How can I contact Palatin Technologies? Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200. This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
